Orphan Diseases Market | Top Key Players - Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French)

An orphan disease is defined as a disorder that affects fewer than 200,000 people in America annually. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unaware as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases have patient populations of less than a hundred. Mutually, however, they affect as many as 25 million Americans every year, according to the National Institutes of Health (NIH), and that makes the diseases--and finding treatments for them-a serious public health concern.

Get a sample report at https://www.marketresearchfuture.com/sample_request/2547 .

New rare diseases are revealed every year. Most are hereditary and caused by adjustments or defects in genes (mutations). Others can be developed as a result of environmental and toxic conditions. Genes are pieces of DNA, part of the code that regulates the traits and discrete characteristics of all living things. Each human cell contains around 30,000 genes. Besides impelling features such as eye and hair colour, genes also can play a role in the development of diseases and in their transmission from parent to child.

As distinct as rare diseases are, patients share many common frustrations. For example, for one-third of people with a rare disease, getting a precise diagnosis can take one to five years. And people often are so isolated that they may never know anyone else with the same disease. Patients often must travel long distances to visit the few doctors knowledgeable about their diseases, and the costs involved with diagnosis, treatment, and other related expenses can be inflated

Before the passage of uncommon diseases laws in the United States, patients diagnosed with a rare disease were deprived of access to effective medicines because prescription drug manufacturers hardly could make a profit from marketing drugs to such small groups. Subsequently, the prescription drug industry did not effectively fund research for orphan product development. Other potential sources, such as research hospitals and universities, also required the capital and business proficiency to develop treatments for small patient groups. In spite of the urgent health need for these medicines, they came to be known as orphans because companies were not concerned in adopting them.

This changed in 1983 when Congress passed the Orphan Drug Act (ODA). The ODA bent financial incentives for drug and biologics manufacturers, comprising of tax credits for costs of clinical research, government grant funding, assistance for clinical research, and a seven-year period of élite marketing given to the first sponsor of an orphan-designated product who achieves market approval from the Food and Drug Administration for the same indication. At the same time, federal programs at the FDA and the NIH initiated encouraging product development, as well as clinical research for products directing rare diseases

Further With a robust pipeline in place, it is analysed where the industry’s current vision lies and highlighted a number of efforts which have been taken by pharmaceutical companies, healthcare organizations and other industry stakeholders. Precisely, our market potential analysis outlines key patient demographics and underscores potential areas estimated to emerge as major revenue initiators for the pharmaceutical companies.

There are various players operating in the global Orphan Diseases market, some of the major players are Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US) and others

More inquire at https://www.marketresearchfuture.com/enquiry/2547 .

Global Orphan Diseases Market   - Regional Analysis

Depending on geographic region, Orphan diseases Market is segmented into four key regions: Americas, Europe, Asia-Pacific, and Middle East & Africa. Considering the global scenario of the market, North America comprise largest market share in Orphan diseases. Moreover the European market is also growing continuously and slowly catching up with the American market in the near future. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the Orphan diseases segment during the forecasted period. Rest of the World is likely to have a limited but steady growth in the market.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
P: +1 646 845 9312
W: www.marketresearchfuture.com
sales@marketresearchfuture.com

This release was published on openPR.